- Recommendation ID
- NG130/6
- Question
What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?
- Any explanatory notes
(if applicable)
Source guidance details
- Comes from guidance
- Ulcerative colitis: management
- Number
- NG130
- Date issued
- May 2019
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |